Cosmetic composition comprising mixture of baicalin and petroselinic acid for improving skin condition

Abstract

The present invention relates to a cosmetic composition comprising a mixture of baicalin and petroselinic acid, and use thereof for improving skin condition. The mixture of baicalin and petroselinic acid has remarkably excellent sensitive skin alleviation, inflammation reduction, skin barrier enhancement or skin-moisturizing effects, and thus can be effectively used in a cosmetic composition for improving skin condition.

Description

Cosmetic composition for improving skin condition comprising a mixture of baicalin and petroselinic acid

[0001] The present invention relates to a cosmetic composition for improving skin condition comprising a mixture of baicalin and petroselinic acid.

[0002] Sensitive skin is a condition in which it reacts hypersensitively to external stimuli, causing symptoms such as inflammation, redness, itching, and stinging; this is associated with the overactivation of the skin's neurological and inflammatory responses. In particular, the activation of TRPV1 (Transient Receptor Potential Vanilloid-1) increases the influx of intracellular calcium ions, amplifying the skin's neurological hypersensitivity and inflammation. Furthermore, cGRP (Calcitonin Gene-Related Peptide) and Substance P are key neuropeptides that induce inflammatory responses and vasodilation in the nervous system, and their excessive release exacerbates the symptoms of sensitive skin. This process can lead to damage to the skin barrier and moisture loss.

[0003] Meanwhile, the overexpression of interleukin-1β (IL-1β), which regulates skin inflammation, exacerbates skin sensitivity and inflammation, while a decrease in skin barrier proteins such as claudin-1 (CLDN-1) and filaggrin (FLG) leads to weakening of the skin barrier and moisture loss. At the same time, aquaporin-3 (AQP3) and hyaluronic acid synthase-3 (HAS3) are responsible for skin moisture transport and hyaluronic acid production, respectively, and a decrease in their expression causes skin dryness and reduced elasticity.

[0004] Therefore, there is a need to develop a cosmetic composition capable of simultaneously inhibiting the expression of CGRP and Substance P, inhibiting intracellular calcium ion influx, inhibiting IL-1β expression, promoting CLDN-1 and FLG expression, and promoting AQP3 and HAS3 expression.

[0005] One aspect provides a cosmetic composition for improving skin condition comprising a mixture of baicalin and petroselinic acid.

[0006] Another aspect provides a topical skin composition for improving skin condition comprising a mixture of baicalin and petroselinic acid.

[0007] Another aspect is to provide a pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising a mixture of baicalin and petroselinic acid.

[0008] Another aspect provides a method for improving the skin condition of an individual, comprising the step of treating or administering a composition containing a mixture of baicalin and petroselinic acid to an individual in need thereof.

[0009] Another aspect provides a method for preventing, improving, or treating the condition of an individual, comprising the step of treating or administering a pharmaceutical composition containing a mixture of baicalin and petroselinic acid to an individual in need thereof.

[0010] Another aspect is to provide a use for improving skin conditions of a composition comprising a mixture of baicalin and petroselinic acid.

[0011] Another aspect provides the use of a mixture of baicalin and petroselinic acid for the preparation of cosmetic compositions for improving skin condition, topical skin compositions for improving skin condition, or pharmaceutical compositions for the prevention or treatment of inflammatory diseases.

[0012] One aspect provides a cosmetic composition for improving skin condition comprising a mixture of baicalin and petroselinic acid.

[0013] The above "baicalin" is a flavonoid compound extracted from the root of *Scutellaria baicalensis*. The method of obtaining the above baicalin is not particularly limited, and, for example, it can be synthesized directly or purchased and used commercially.

[0014] The above "petro-selinic acid" is an unsaturated fatty acid found mainly in the seeds of plants of the Apiaceae family. The method of obtaining the above petro-selinic acid is not particularly limited; for example, it can be extracted from plants or purchased commercially.

[0015] The molecular ratio of the baicalin and the petroselinic acid in the above mixture may be 1:1 to 8:1, 1:1 to 6:1, 1:1 to 4:1, 2:1 to 8:1, 2:1 to 6:1, 2:1 to 4:1, 4:1 to 8:1, or 4:1 to 6:1, for example, 4:1, but is not particularly limited thereto. The molecular ratio of the baicalin and the petroselinic acid may be selected as an appropriate molecular ratio within a molecular ratio range sufficient to produce the effects mentioned herein by a person skilled in the art.

[0016] In this specification, the term “molecular ratio” refers to the ratio between the number of molecules of each component in a mixture.

[0017] According to one embodiment, the mixed molecular ratio of the baicalin and the petroselinic acid may be 2:1 to 6:1, and within the range of the mixed molecular ratio, significantly superior efficacy in improving sensitive skin, efficacy in improving the skin barrier, and efficacy in moisturizing the skin may be exhibited.

[0018] The above baicalin may be included in an amount of 0.00006 to 44.52 weight%, 0.00006 to 22.3 weight%, 0.00074 to 44.52 weight%, or 0.00074 to 22.3 weight% relative to the total weight of the cosmetic composition, but is not particularly limited thereto. The content of the above baicalin may be selected as an appropriate amount within a range sufficient to produce the effects mentioned in this specification by a person skilled in the art.

[0019] Petrocelinic acid may be included in an amount of 0.00002 to 7.05 weight%, 0.00002 to 4.7 weight%, 0.000078 to 7.05 weight%, or 0.000078 to 4.7 weight% relative to the total weight of the cosmetic composition, but is not particularly limited thereto. The content of the petroselinic acid may be selected as an appropriate amount within a range sufficient to produce the effects mentioned in this specification by a person skilled in the art.

[0020] The above skin condition improvement may be improvement of sensitive skin, improvement of inflammation, improvement of the skin barrier, or skin moisturization.

[0021] The aforementioned “sensitive skin” refers to skin that reacts more sensitively to environmental changes, such as external stimuli or allergens, compared to normal skin, and is prone to irritation reactions or dermatitis. A representative example of sensitive skin is atopic dermatitis, but it is not limited thereto. The causes of sensitive skin are very diverse and complex; it may be caused by congenital sensitivity due to genetic factors, or by external factors such as harmful substances, stress, climate, seasonal changes, and the work environment. The causes inducing sensitive skin broadly include neurological overreactions, increased immune responses, and damage to the skin barrier; while cases resulting from skin barrier damage are primarily observed, they are not limited to this. Furthermore, it may be accompanied by symptoms such as erythema, skin dryness, stinging, itching, burning, and inflammation, but is not limited thereto.

[0022] The above “improvement of sensitive skin” refers to any action that reduces the occurrence of sensitive skin, reduces the severity of symptoms such as erythema, skin dryness, heat sensation, pain, stinging, itching, and burning, or restores damaged skin, and may include the concept of alleviating skin irritation or soothing the skin.

[0023] The above "strengthening of the skin barrier" may refer to any action that enhances the function of the skin barrier, which is located on the outermost layer of the skin and prevents the loss of moisture and nutrients.

[0024] The term "improvement of inflammation" above may be used interchangeably with "anti-inflammation" and "inflammation suppression," and may include, for example, all actions that suppress the expression of inflammatory cytokines.

[0025] The above "skin moisturization" may refer to any action that maintains skin moisture or prevents moisture loss.

[0026] In one embodiment, the cosmetic composition may reduce or inhibit the influx of calcium ions into cells, or reduce or inhibit the expression of cGRP (Calcitonin Gene-Related Peptide) or Substance P. Accordingly, the cosmetic composition may exhibit an effect of improving sensitive skin. Since the cosmetic composition includes a mixture of baicalin and petroselinic acid, the effect of inhibiting the influx of calcium ions into cells or inhibiting the expression of cGRP (Calcitonin Gene-Related Peptide) or Substance P is statistically significantly superior compared to when each component is used alone, it may exhibit a synergistic effect in improving sensitive skin.

[0027] In one embodiment, the cosmetic composition may reduce or inhibit the expression of Interleukin-1β (IL-1β). Accordingly, the cosmetic composition may exhibit an effect of improving inflammation in companion animals. Since the cosmetic composition includes a mixture of baicalin and petroselinic acid, the inhibitory effect on IL-1β expression is statistically significantly superior compared to when each component is used alone, thus exhibiting a synergistic effect in improving inflammation.

[0028] In one embodiment, the composition may increase or promote the expression of Claudin-1 (CLDN-1) or Filaggrin (FLG). Accordingly, the cosmetic composition may exhibit a skin barrier improvement effect. Since the cosmetic composition includes a mixture of baicalin and petroselinic acid, the effect of promoting the expression of CLDN-1 or FLG is statistically significantly superior compared to when each component is used alone, thus exhibiting a synergistic effect in improving the skin barrier.

[0029] In one embodiment, the composition may increase or promote the expression of Aquaporin-3 (AQP3) or Hyaluronic Acid Synthase-3 (HAS3). Accordingly, the cosmetic composition may exhibit a skin moisturizing effect. Since the cosmetic composition includes a mixture of baicalin and petroselinic acid, the effect of promoting the expression of AQP3 or HAS3 is statistically significantly superior compared to when each component is used alone, thus exhibiting a synergistic effect on skin moisturization.

[0030]

[0031] The above cosmetic composition may additionally include ingredients commonly used in cosmetic compositions, functional additives, etc., in addition to the active ingredients disclosed in this specification, and may include, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, preservatives, vitamins, pigments, fragrances, etc., and carriers.

[0032] The above cosmetic composition is not specifically limited to a particular formulation, and the formulation may be appropriately selected according to the purpose. The above cosmetic composition may have, for example, a solubilized formulation, an emulsified formulation, or a dispersed formulation. The above cosmetic composition may have, for example, a lotion, a cream, an essence, a cleansing foam, a cleansing water, a pack, an ampoule, a body lotion, a body oil, a body gel, a shampoo, a rinse, a hair conditioner, a hair gel, a foundation, a lipstick, a mascara, a makeup base, or a skin-adhesive type cosmetic formulation. The above skin-adhesive type cosmetic formulation may be, for example, a mask pack, but is not limited thereto.

[0033]

[0034] Another aspect provides a topical skin composition for improving skin condition comprising a mixture of baicalin and petroselinic acid. In the topical skin composition, the terms and elements mentioned are identical to those already mentioned.

[0035] The above topical skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof.

[0036] The above-mentioned topical preparation may be appropriately formulated with ingredients commonly used in topical preparations for the skin, such as cosmetics or pharmaceuticals, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof as needed. The above-mentioned topical preparation may also appropriately formulate metal chelating agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannins, bellapamil, licorice extract, glablidin, various herbal medicines; preparations such as tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts thereof; vitamin C, magnesium ascorbate phosphate, ascorbate glucoside, arbutin, or kojic acid.

[0037]

[0038] Another aspect provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising a mixture of baicalin and petroselinic acid. In the pharmaceutical composition, the terms and elements mentioned are identical to those already mentioned.

[0039] The above "prevention" may refer to any act in which the possibility of onset of skin-related diseases is suppressed or delayed by the administration of the composition of the present invention.

[0040] The above "treatment" may refer to any act of improving or beneficially altering the symptoms of skin-related diseases by administering the composition of the present invention.

[0041] The above “inflammatory disease” may be one or more selected from the group consisting of inflammatory skin diseases and allergic inflammatory diseases.

[0042] The above “inflammatory skin disease” may be one or more selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, seborrheic dermatitis and acne.

[0043] The above pharmaceutical composition may additionally comprise a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium anhydrous phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

[0044] The above pharmaceutical composition may be formulated into an oral or parenteral administration formulation. The oral administration formulation may be a granule, powder, liquid, tablet, capsule, dry syrup, or a combination thereof. The parenteral administration formulation may be an injection.

[0045]

[0046] Another aspect provides a method for improving the skin condition of an individual, comprising the step of treating or administering a composition containing a mixture of baicalin and petroselinic acid to an individual in need thereof. In the method, the same as those previously mentioned among the mentioned term elements are as described above.

[0047] Another aspect provides a method for preventing, improving, or treating the condition of an individual, comprising the step of treating or administering a pharmaceutical composition containing a mixture of baicalin and petroselinic acid to an individual in need thereof. The condition of the individual may be an inflammatory disease. In the method, the terms and elements mentioned are identical to those already mentioned.

[0048] In this specification, the terms “treatment,” “administration,” “introduction,” “application,” and “implantation” are used interchangeably and may mean applying a composition according to one embodiment to the body or skin of an individual to reach a target site.

[0049] The above treatment or administration may be carried out by methods known in the art. The site, frequency, amount, etc., of the above treatment or administration can be appropriately selected by a person skilled in the art.

[0050] For example, the above composition may be administered directly to an individual by any means, via routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, subcutaneous administration, or topical application. The administration may be systemic or local. The administration may include application to the skin or mucous membranes.

[0051] For example, the above composition may be applied to the skin by methods such as direct application, spraying, massage, or spreading. The treatment may be performed locally or entirely on specific parts of the body, such as the face, neck, arms, and legs, or on the entire body.

[0052] The above-mentioned individual may be a mammal, for example, a human, cattle, horses, pigs, dogs, sheep, goats, or cats. In one embodiment, the above-mentioned individual may be an individual requiring improvement of skin condition. In one embodiment, the above-mentioned individual may be an individual requiring prevention, improvement, or treatment of an inflammatory disease.

[0053]

[0054] Another aspect provides a use for improving skin conditions of a composition comprising a mixture of baicalin and petroselinic acid. In the said use, the same as those previously mentioned among the mentioned term elements are as described above.

[0055] Another aspect provides the use of a mixture of baicalin and petroselinic acid for the preparation of cosmetic compositions for improving skin condition, topical skin compositions for improving skin condition, or pharmaceutical compositions for the prevention or treatment of inflammatory diseases. In the above use, the same as those previously mentioned among the mentioned term elements are as described above.

[0056] A cosmetic composition according to one aspect comprises a mixture of baicalin and petroselinic acid, thereby having significant synergistic effects such as improving sensitive skin, reducing inflammation, improving the skin barrier, and moisturizing the skin.

[0057] Figures 1a and 1b show the effect of inhibiting calcium ion influx by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0058] Figure 2 is a figure confirming the inhibitory effect of intracellular baicalin and petroselinic acid on cGRP expression by treatment alone or in combination.

[0059] Figure 3 is a figure confirming the inhibitory effect of Substance P expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0060] Figure 4 is a figure confirming the inhibitory effect of intracellular baicalin and petroselinic acid on IL-1β expression by treatment alone or in combination.

[0061] Figure 5 is a figure confirming the effect of promoting CLDN-1 expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0062] Figure 6 is a figure confirming the effect of promoting FLG expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0063] Figure 7 is a figure confirming the effect of promoting AQP3 expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0064] Figure 8 is a figure confirming the effect of promoting HAS3 expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0065] The following examples will be explained in more detail. However, these examples are intended to illustrate one or more specific examples, and the scope of the present invention is not limited to these examples.

[0066]

[0067] Example 1: Preparation of a sample containing a mixture of baicalin and petroselinic acid

[0068] Baicalin (Sigma Aldrich, 572667, CAS 21967-41-9) and petroselinic acid (Santa Cruz, SC-215696, CAS 593-39-5) were prepared separately, dissolved in dimethyl sulfoxide (DMSO), and samples were prepared by mixing baicalin and petroselinic acid at molecular ratios of 1:1, 2:1, 4:1, 6:1, and 8:1, respectively.

[0069]

[0070] Experimental Example 1: Confirmation of efficacy in improving skin condition

[0071] To confirm the skin sensitivity improvement, inflammation improvement, skin barrier improvement, and skin moisturizing efficacy of the cosmetic composition of the above example, the intracellular calcium ion influx level and the expression levels of cGRP, Substance P, IL-1β, CLDN-1, FLG, AQP3, and HAS3 were analyzed.

[0072]

[0073] 1-1. Experimental Method

[0074] (1) Cell culture and sample processing

[0075] HaCaT (keratinocytes), which are stratum corneum cells, were treated with either baicalin and petroselinic acid alone or a mixture of baicalin and petroselinic acid prepared in Preparation Example 1, respectively, and cultured for an additional 24 hours. Subsequently, sensitizing stimulation was induced by treating the cells with 0.2% lactic acid. The group without lactic acid treatment (None) was designated as the negative control, and the group treated with lactic acid + without the sample (None) was designated as the non-treatment control.

[0076]

[0077] (2) Calcium Influx Reaction Analysis

[0078] The level of intracellular calcium ion influx was analyzed using the following method. After treating the cells with the evaluation material for 24 hours, the culture medium was removed and the cells were washed with phosphate-buffered saline (PBS). The culture medium was then replaced with one containing 1 μM Fluor-3 and 0.04% F127 solution for calcium fluorescent labeling, and the cells were incubated for 1 hour. After the 1-hour reaction, 0.2% lactic acid was added, and the intracellular calcium influx signal over time was measured via fluorescence photography. The intensity of the calcium fluorescence signal was analyzed by quantifying the signal intensity per unit cell area using the Image J program.

[0079] (3) Analysis of gene expression levels

[0080] The expression levels of cGRP, Substance P, IL-1β, CLDN-1, FLG, AQP3, and HAS3 were analyzed using the following methods. After treating cells with the evaluation material for 24 hours, the culture medium was removed and the cells were washed with phosphate-buffered saline (PBS). Subsequently, a culture medium containing 0.2% lactic acid was treated for 4 hours to induce sensitivity stimulation. Cell mRNA expression levels were measured via qRT-PCR analysis and compared based on beta-actin expression levels.

[0081]

[0082] 1-2. Results

[0083] (1) Confirmation of efficacy in improving sensitive skin

[0084] Figures 1a and 1b show the effect of inhibiting calcium ion influx by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0085] As a result, as shown in Figures 1a and 1b, intracellular calcium ion influx increased with lactic acid treatment, but calcium ion influx was significantly inhibited by baicalin and petroselinic acid treatment alone or in combination. In particular, it was confirmed that the mixture of baicalin and petroselinic acid had a significantly superior effect in inhibiting intracellular calcium ion influx compared to each component alone. Specifically, the effect of inhibiting intracellular calcium ion influx was significantly superior when baicalin and petroselinic acid were included in a molecular ratio of 2:1 to 6:1 compared to when they were included in a molecular ratio of 1:1 or 8:1, and it was confirmed that the effect of inhibiting calcium ion influx was best at a molecular ratio of 4:1.

[0086] Figure 2 is a figure confirming the inhibitory effect of intracellular baicalin and petroselinic acid on cGRP expression by treatment alone or in combination.

[0087] Figure 3 is a figure confirming the inhibitory effect of Substance P expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0088] As a result, as shown in Figures 2 and 3, the expression of cGRP and Substance P was increased by lactic acid treatment, but the expression of cGRP and Substance P was significantly inhibited by baicalin and petroselinic acid treatment alone or in combination. In particular, it was confirmed that the mixture of baicalin and petroselinic acid had a significantly superior inhibitory effect on the expression of cGRP and Substance P compared to each component alone. Specifically, the inhibitory effect on the expression of cGRP and Substance P was significantly superior when baicalin and petroselinic acid were included in a molecular ratio of 2:1 to 6:1 compared to when they were included in a molecular ratio of 1:1 or 8:1, and it was confirmed that the inhibitory effect on the expression of cGRP and Substance P was best at a molecular ratio of 4:1.

[0089] Therefore, it was confirmed that a mixture of baicalin and petroselinic acid can exhibit a synergistic effect in improving sensitive skin.

[0090]

[0091] (2) Confirmation of efficacy in improving inflammation

[0092] Figure 4 is a figure confirming the inhibitory effect of intracellular baicalin and petroselinic acid on IL-1β expression by treatment alone or in combination.

[0093] As a result, as shown in Figure 4, the expression of IL-1β was increased by lactic acid treatment, but the expression of IL-1β was significantly inhibited by baicalin and petroselinic acid treatment alone or in combination. In particular, it was confirmed that the mixture of baicalin and petroselinic acid had a significantly superior effect in inhibiting IL-1β expression compared to each component alone. Specifically, the inhibitory effect on IL-1β expression was significantly superior when baicalin and petroselinic acid were included in a molecular ratio of 2:1 to 6:1 compared to when they were included in a molecular ratio of 1:1 or 8:1, and it was confirmed that the inhibitory effect on IL-1β expression was best at a molecular ratio of 4:1.

[0094] Therefore, it was confirmed that a mixture of baicalin and petroselinic acid can exhibit a synergistic effect in improving inflammation.

[0095]

[0096] (3) Confirmation of skin barrier improvement efficacy

[0097] Figure 5 is a figure confirming the effect of promoting CLDN-1 expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0098] Figure 6 is a figure confirming the effect of promoting FLG expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0099] As a result, as shown in Figures 5 and 6, the expression of CLDN-1 and FLG was reduced by lactic acid treatment, but the expression of CLDN-1 and FLG was significantly promoted by baicalin and petroselinic acid treatment alone or in combination. In particular, it was confirmed that the mixture of baicalin and petroselinic acid had a significantly superior effect in promoting the expression of CLDN-1 and FLG compared to each component alone. Specifically, the effect of promoting the expression of CLDN-1 and FLG was significantly superior when baicalin and petroselinic acid were included in a molecular ratio of 2:1 to 6:1 compared to when they were included in a molecular ratio of 1:1 or 8:1, and it was confirmed that the effect of promoting the expression of CLDN-1 and FLG was best at a molecular ratio of 4:1.

[0100] Therefore, it was confirmed that a mixture of baicalin and petroselinic acid can exhibit a synergistic effect in improving the skin barrier.

[0101]

[0102] (4) Confirmation of skin moisturizing efficacy

[0103] Figure 7 is a figure confirming the effect of promoting AQP3 expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0104] Figure 8 is a figure confirming the effect of promoting HAS3 expression by intracellular treatment with baicalin and petroselinic acid alone or in combination.

[0105] As a result, as shown in Figures 5 and 6, the expression of AQP3 and HAS3 was reduced by lactic acid treatment, but the expression of AQP3 and HAS3 was significantly promoted by baicalin and petroselinic acid treatment alone or in combination. In particular, it was confirmed that the mixture of baicalin and petroselinic acid had a significantly superior effect in promoting the expression of AQP3 and HAS3 compared to each component alone. Specifically, the effect of promoting the expression of AQP3 and HAS3 was significantly superior when baicalin and petroselinic acid were included in a molecular ratio of 2:1 to 6:1 compared to when they were included in a molecular ratio of 1:1 or 8:1, and it was confirmed that the effect of promoting the expression of AQP3 and HAS3 was best at a molecular ratio of 4:1.

[0106] Therefore, it was confirmed that a mixture of baicalin and petroselinic acid can exhibit a synergistic effect on skin moisturization.

[0107]

[0108] Sintering

[0109] Therefore, since the mixture of baicalin and petroselinic acid exhibits significantly superior efficacy in improving sensitive skin, reducing inflammation, improving the skin barrier, or moisturizing the skin, a cosmetic composition containing the mixture of baicalin and petroselinic acid is expected to be used as a cosmetic composition for improving sensitive skin, reducing inflammation, improving the skin barrier, or moisturizing the skin.

Claims

1. A cosmetic composition for improving skin condition comprising a mixture of baicalin and petroselinic acid.

2. A cosmetic composition according to claim 1, wherein the mixing molecular ratio of the baicalin and the petroselinic acid is 1:1 to 8:

1.

3. A cosmetic composition according to claim 1, wherein the improvement of the skin condition is improvement of sensitive skin, improvement of inflammation, improvement of the skin barrier, or skin moisturization.

4. A topical skin composition for improving skin condition comprising a mixture of baicalin and petroselinic acid.

5. A pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising a mixture of baicalin and petroselinic acid.

6. A method for improving the skin condition of an individual, comprising the step of treating or administering a composition containing a mixture of baicalin and petroselinic acid to an individual in need thereof.

7. A method for preventing, improving, or treating the condition of an individual, comprising the step of treating or administering a pharmaceutical composition containing a mixture of baicalin and petroselinic acid to an individual in need thereof.

8. Use of a composition comprising a mixture of baicalin and petroselinic acid for improving skin condition.

9. Use of a mixture of baicalin and petroselinic acid for the preparation of a pharmaceutical composition for the prevention or treatment of inflammatory diseases.

Images